"Polyethylene Glycols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS.
| Descriptor ID |
D011092
|
| MeSH Number(s) |
D02.033.455.250.700 D05.750.741 D25.720.741 J01.637.051.720.741
|
| Concept/Terms |
Polyethylene Glycols- Polyethylene Glycols
- Macrogols
- Macrogol
- Polyethylene Glycol
- Glycol, Polyethylene
- Glycols, Polyethylene
- Polyethylene Oxide
- Oxide, Polyethylene
- Oxides, Polyethylene
- Polyethylene Oxides
- Polyethyleneoxide
- Polyethyleneoxides
- Polyoxyethylenes
- Polyoxyethylene
- Tritons
|
Below are MeSH descriptors whose meaning is more general than "Polyethylene Glycols".
Below are MeSH descriptors whose meaning is more specific than "Polyethylene Glycols".
This graph shows the total number of publications written about "Polyethylene Glycols" by people in this website by year, and whether "Polyethylene Glycols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 2 | 3 |
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 2 | 3 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 1 | 2 | 3 |
| 2005 | 1 | 1 | 2 |
| 2006 | 2 | 1 | 3 |
| 2007 | 5 | 3 | 8 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 4 | 6 |
| 2010 | 5 | 2 | 7 |
| 2011 | 3 | 6 | 9 |
| 2012 | 8 | 7 | 15 |
| 2013 | 12 | 1 | 13 |
| 2014 | 6 | 5 | 11 |
| 2015 | 5 | 6 | 11 |
| 2016 | 4 | 1 | 5 |
| 2017 | 4 | 3 | 7 |
| 2018 | 2 | 6 | 8 |
| 2019 | 4 | 1 | 5 |
| 2020 | 3 | 4 | 7 |
| 2021 | 2 | 5 | 7 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 3 | 3 |
| 2024 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Polyethylene Glycols" by people in Profiles.
-
CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. Future Oncol. 2024; 20(37):2915-2925.
-
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 2024 Dec; 38(12):2717-2721.
-
Citrulline and ADI-PEG20 reduce inflammation in a juvenile porcine model of acute endotoxemia. Front Immunol. 2024; 15:1400574.
-
Preparation and characterization of the injectable pH- and temperature-sensitive pentablock hydrogel containing human growth hormone-loaded chitosan nanoparticles via electrospraying. J Biomater Sci Polym Ed. 2024 09; 35(13):1999-2019.
-
Loss of Dnmt3a increases self-renewal and resistance to pegIFN-a in JAK2-V617F-positive myeloproliferative neoplasms. Blood. 2024 06 13; 143(24):2490-2503.
-
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09). J Clin Oncol. 2024 Aug 10; 42(23):2800-2811.
-
Ultra-pH-sensitive nanoparticle of gambogenic acid for tumor targeting therapy via anti-vascular strategy plus immunotherapy. Int J Pharm. 2024 Jul 20; 660:124303.
-
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncol. 2024 Apr 01; 10(4):475-483.
-
Polyethylene Glycol-Mediated Axonal Fusion Promotes Early Sensory Recovery after Digital Nerve Injury: A Randomized Clinical Trial. Plast Reconstr Surg. 2024 Dec 01; 154(6):1247-1256.
-
HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia. Eur J Haematol. 2024 Mar; 112(3):392-401.